Impact	O
of	O
LbSapSal	B:C0042210
Vaccine	I:C0042210
in	O
Canine	O
Immunological	O
and	O
Parasitological	O
Features	O
before	O
and	O
after	O
Leishmania	O
chagasi	I:C0446195
-	O
Challenge	O
.	O

Impact	O
of	O
LbSapSal	O
Vaccine	I:C0042210
in	O
Canine	B:C1280551
Immunological	O
and	O
Parasitological	O
Features	O
before	O
and	O
after	O
Leishmania	O
chagasi	I:C0446195
-	O
Challenge	O
.	O

Impact	O
of	O
LbSapSal	O
Vaccine	I:C0042210
in	O
Canine	O
Immunological	O
and	O
Parasitological	O
Features	O
before	O
and	O
after	O
Leishmania	B:C0446195
chagasi	I:C0446195
-	O
Challenge	O
.	O

Impact	O
of	O
LbSapSal	O
Vaccine	I:C0042210
in	O
Canine	O
Immunological	O
and	O
Parasitological	O
Features	O
before	O
and	O
after	O
Leishmania	O
chagasi	I:C0446195
-	O
Challenge	B:C0805586
.	O

Dogs	B:C0012984
represent	O
the	O
most	O
important	O
domestic	O
reservoir	O
of	O
L.	O
chagasi	I:C0446195
(	O
syn.	O
L.	O
infantum	I:C0023272
)	O
.	O

Dogs	O
represent	O
the	O
most	O
important	O
domestic	O
reservoir	O
of	O
L.	B:C0446195
chagasi	I:C0446195
(	O
syn.	O
L.	O
infantum	I:C0023272
)	O
.	O

Dogs	O
represent	O
the	O
most	O
important	O
domestic	O
reservoir	O
of	O
L.	O
chagasi	I:C0446195
(	O
syn.	O
L.	B:C0023272
infantum	I:C0023272
)	O
.	O

A	O
vaccine	B:C0042210
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	B:C1280551
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	B:C0023290
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	B:C0023290
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	B:C0003467
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	B:C0086418
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	B:C0023290
leishmaniasis	I:C0023290
(	O
visceral	O
leishmaniasis	I:C0023290
)	O
.	O

A	O
vaccine	O
against	O
canine	O
visceral	O
leishmaniasis	I:C0023290
(	O
canine	O
visceral	I:C0023290
leishmaniasis	I:C0023290
)	O
would	O
be	O
an	O
important	O
tool	O
for	O
decreasing	O
the	O
anxiety	O
related	O
to	O
possible	O
L.	O
chagasi	O
infection	O
and	O
for	O
controlling	O
human	O
visceral	O
leishmaniasis	I:C0023290
(	O
visceral	B:C0023290
leishmaniasis	I:C0023290
)	O
.	O

Because	O
the	O
sand	B:C0036158
fly	I:C0036158
salivary	O
proteins	I:C0036100
are	O
potent	O
immunogens	O
obligatorily	O
co-deposited	O
during	O
transmission	O
of	O
Leishmania	O
parasites	I:C1095819
,	O
their	O
inclusion	O
in	O
an	O
anti-Leishmania	O
vaccine	I:C1548483
has	O
been	O
investigated	O
in	O
past	O
decades	O
.	O

Because	O
the	O
sand	O
fly	I:C0036158
salivary	B:C0036100
proteins	I:C0036100
are	O
potent	O
immunogens	O
obligatorily	O
co-deposited	O
during	O
transmission	O
of	O
Leishmania	O
parasites	I:C1095819
,	O
their	O
inclusion	O
in	O
an	O
anti-Leishmania	O
vaccine	I:C1548483
has	O
been	O
investigated	O
in	O
past	O
decades	O
.	O

Because	O
the	O
sand	O
fly	I:C0036158
salivary	O
proteins	I:C0036100
are	O
potent	O
immunogens	B:C0003320
obligatorily	O
co-deposited	O
during	O
transmission	O
of	O
Leishmania	O
parasites	I:C1095819
,	O
their	O
inclusion	O
in	O
an	O
anti-Leishmania	O
vaccine	I:C1548483
has	O
been	O
investigated	O
in	O
past	O
decades	O
.	O

Because	O
the	O
sand	O
fly	I:C0036158
salivary	O
proteins	I:C0036100
are	O
potent	O
immunogens	O
obligatorily	O
co-deposited	O
during	O
transmission	O
of	O
Leishmania	B:C1095819
parasites	I:C1095819
,	O
their	O
inclusion	O
in	O
an	O
anti-Leishmania	O
vaccine	I:C1548483
has	O
been	O
investigated	O
in	O
past	O
decades	O
.	O

Because	O
the	O
sand	O
fly	I:C0036158
salivary	O
proteins	I:C0036100
are	O
potent	O
immunogens	O
obligatorily	O
co-deposited	O
during	O
transmission	O
of	O
Leishmania	O
parasites	I:C1095819
,	O
their	O
inclusion	O
in	O
an	O
anti-Leishmania	B:C1548483
vaccine	I:C1548483
has	O
been	O
investigated	O
in	O
past	O
decades	O
.	O

We	O
investigated	O
the	O
immunogenicity	B:C4277607
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	B:C0042210
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	B:C0023271
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	B:C0003320
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	B:C0520481
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	B:C0001551
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	B:C0322761
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	B:C0036098
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	B:C0012984
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	B:C0446195
chagasi	I:C0446195
-	O
challenge	O
.	O

We	O
investigated	O
the	O
immunogenicity	O
of	O
the	O
"	O
LbSapSal	I:C0042210
"	I:C0042210
vaccine	I:C0042210
(	O
L.	O
braziliensis	I:C0023271
antigens	O
,	O
saponin	O
as	O
adjuvant	O
,	O
and	O
Lutzomyia	O
longipalpis	I:C0322761
salivary	O
gland	I:C0036098
extract	O
)	O
in	O
dogs	O
at	O
baseline	O
(	O
T0	O
)	O
,	O
during	O
the	O
post	O
-	O
vaccination	O
protocol	O
(	O
T3rd	O
)	O
and	O
after	O
early	O
(	O
T90	O
)	O
and	O
late	O
(	O
T885	O
)	O
times	O
following	O
L.	O
chagasi	I:C0446195
-	O
challenge	B:C0805586
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	B:C0020971
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	B:C0042210
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	B:C0005516
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	B:C0041368
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	B:C1456820
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	B:C0123759
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	B:C0021745
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	B:C0079189
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	B:C0079189
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	B:C0021758
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	B:C0040690
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	O
.	O

Our	O
major	O
data	O
indicated	O
that	O
immunization	O
with	O
"	O
LbSapSal	O
"	O
is	O
able	O
to	O
induce	O
biomarkers	O
characterized	O
by	O
enhanced	O
amounts	O
of	O
type	O
I	I:C0041368
(	O
tumor	O
necrosis	I:C1456820
factor	I:C1456820
[	I:C1456820
TNF	I:C1456820
]	I:C1456820
-α	I:C1456820
,	O
interleukin	O
[	I:C0123759
IL	I:C0123759
]	I:C0123759
-	I:C0123759
12	I:C0123759
,	O
interferon	O
[	I:C0021745
IFN	I:C0021745
]	I:C0021745
-γ	I:C0021745
)	O
cytokines	O
and	O
reduction	O
in	O
type	O
II	I:C0079189
cytokines	I:C0079189
(	O
IL	O
-	I:C0021758
4	I:C0021758
and	O
TGF	O
-β	I:C0040690
)	O
,	O
even	O
after	O
experimental	O
challenge	B:C0805586
.	O

The	O
establishment	O
of	O
a	O
prominent	O
pro-inflammatory	O
immune	B:C0301872
response	I:C0301872
after	O
"	O
LbSapSal	O
"	O
immunization	O
supported	O
the	O
increased	O
levels	O
of	O
nitric	O
oxide	I:C0028128
production	O
,	O
favoring	O
a	O
reduction	O
in	O
spleen	O
parasitism	O
(	O
78.9	O
%	O
)	O
and	O
indicating	O
long	O
-	O
lasting	O
protection	O
against	O
L.	O
chagasi	O
infection	O
.	O

The	O
establishment	O
of	O
a	O
prominent	O
pro-inflammatory	O
immune	O
response	I:C0301872
after	O
"	O
LbSapSal	B:C0042210
"	O
immunization	O
supported	O
the	O
increased	O
levels	O
of	O
nitric	O
oxide	I:C0028128
production	O
,	O
favoring	O
a	O
reduction	O
in	O
spleen	O
parasitism	O
(	O
78.9	O
%	O
)	O
and	O
indicating	O
long	O
-	O
lasting	O
protection	O
against	O
L.	O
chagasi	O
infection	O
.	O

The	O
establishment	O
of	O
a	O
prominent	O
pro-inflammatory	O
immune	O
response	I:C0301872
after	O
"	O
LbSapSal	O
"	O
immunization	B:C0020971
supported	O
the	O
increased	O
levels	O
of	O
nitric	O
oxide	I:C0028128
production	O
,	O
favoring	O
a	O
reduction	O
in	O
spleen	O
parasitism	O
(	O
78.9	O
%	O
)	O
and	O
indicating	O
long	O
-	O
lasting	O
protection	O
against	O
L.	O
chagasi	O
infection	O
.	O

The	O
establishment	O
of	O
a	O
prominent	O
pro-inflammatory	O
immune	O
response	I:C0301872
after	O
"	O
LbSapSal	O
"	O
immunization	O
supported	O
the	O
increased	O
levels	O
of	O
nitric	B:C0028128
oxide	I:C0028128
production	O
,	O
favoring	O
a	O
reduction	O
in	O
spleen	O
parasitism	O
(	O
78.9	O
%	O
)	O
and	O
indicating	O
long	O
-	O
lasting	O
protection	O
against	O
L.	O
chagasi	O
infection	O
.	O

The	O
establishment	O
of	O
a	O
prominent	O
pro-inflammatory	O
immune	O
response	I:C0301872
after	O
"	O
LbSapSal	O
"	O
immunization	O
supported	O
the	O
increased	O
levels	O
of	O
nitric	O
oxide	I:C0028128
production	O
,	O
favoring	O
a	O
reduction	O
in	O
spleen	B:C0037993
parasitism	O
(	O
78.9	O
%	O
)	O
and	O
indicating	O
long	O
-	O
lasting	O
protection	O
against	O
L.	O
chagasi	O
infection	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
confirmed	O
the	O
hypothesis	O
that	O
the	O
"	O
LbSapSal	B:C0042210
"	O
vaccination	O
is	O
a	O
potential	O
tool	O
to	O
control	O
the	O
Leishmania	O
chagasi	O
infection	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
confirmed	O
the	O
hypothesis	O
that	O
the	O
"	O
LbSapSal	O
"	O
vaccination	B:C0042196
is	O
a	O
potential	O
tool	O
to	O
control	O
the	O
Leishmania	O
chagasi	O
infection	O
.	O

